Goldman Sachs Group began coverage on shares of CIGNA (NYSE:CI) in a research report issued to clients and investors on Wednesday. The brokerage set a “neutral” rating on the health services provider’s stock.

Several other research firms also recently weighed in on CI. Jefferies Group lifted their target price on CIGNA from $221.00 to $231.00 and gave the stock a “buy” rating in a research report on Friday, November 3rd. Zacks Investment Research downgraded CIGNA from a “buy” rating to a “hold” rating in a research report on Friday, November 10th. ValuEngine upgraded CIGNA from a “hold” rating to a “buy” rating in a research report on Sunday. Piper Jaffray Companies reiterated a “buy” rating and set a $191.00 target price on shares of CIGNA in a research report on Sunday, September 17th. Finally, BMO Capital Markets began coverage on CIGNA in a research report on Monday, October 16th. They set a “market perform” rating and a $210.00 target price for the company. Three investment analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $202.56.

Shares of CIGNA (NYSE:CI) opened at $202.56 on Wednesday. The stock has a market capitalization of $50,071.78, a price-to-earnings ratio of 22.19, a P/E/G ratio of 1.39 and a beta of 0.51. CIGNA has a 52-week low of $133.52 and a 52-week high of $212.46. The company has a debt-to-equity ratio of 0.37, a current ratio of 0.39 and a quick ratio of 0.39.

CIGNA (NYSE:CI) last released its earnings results on Thursday, November 2nd. The health services provider reported $2.83 earnings per share for the quarter, topping the consensus estimate of $2.36 by $0.47. CIGNA had a return on equity of 18.85% and a net margin of 5.74%. The business had revenue of $10.38 billion during the quarter, compared to the consensus estimate of $10.17 billion. During the same period last year, the company earned $1.94 earnings per share. The business’s revenue for the quarter was up 5.1% compared to the same quarter last year. analysts anticipate that CIGNA will post 10.34 EPS for the current year.

In other CIGNA news, CAO Mary T. Hoeltzel sold 575 shares of CIGNA stock in a transaction dated Thursday, November 9th. The stock was sold at an average price of $197.03, for a total value of $113,292.25. Following the transaction, the chief accounting officer now owns 2,499 shares in the company, valued at $492,377.97. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Michael W. Triplett sold 10,417 shares of CIGNA stock in a transaction dated Monday, November 13th. The shares were sold at an average price of $197.77, for a total value of $2,060,170.09. Following the completion of the transaction, the insider now owns 32,347 shares in the company, valued at approximately $6,397,266.19. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 34,936 shares of company stock worth $6,979,204. Insiders own 1.30% of the company’s stock.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Northwestern Mutual Wealth Management Co. grew its stake in CIGNA by 2.3% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 1,760 shares of the health services provider’s stock valued at $295,000 after purchasing an additional 40 shares during the last quarter. Veritable L.P. boosted its holdings in CIGNA by 0.5% in the second quarter. Veritable L.P. now owns 8,220 shares of the health services provider’s stock worth $1,376,000 after acquiring an additional 41 shares in the last quarter. MML Investors Services LLC boosted its holdings in CIGNA by 0.8% in the second quarter. MML Investors Services LLC now owns 5,774 shares of the health services provider’s stock worth $967,000 after acquiring an additional 43 shares in the last quarter. Argent Capital Management LLC boosted its holdings in CIGNA by 2.0% in the second quarter. Argent Capital Management LLC now owns 2,613 shares of the health services provider’s stock worth $437,000 after acquiring an additional 50 shares in the last quarter. Finally, Cambridge Investment Research Advisors Inc. boosted its holdings in CIGNA by 7.9% in the second quarter. Cambridge Investment Research Advisors Inc. now owns 3,629 shares of the health services provider’s stock worth $607,000 after acquiring an additional 265 shares in the last quarter. Institutional investors own 87.74% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “CIGNA (CI) Coverage Initiated at Goldman Sachs Group” was reported by Watch List News and is owned by of Watch List News. If you are accessing this report on another publication, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this report can be read at https://www.watchlistnews.com/cigna-ci-coverage-initiated-at-goldman-sachs-group/1792877.html.

About CIGNA

Cigna Corporation (Cigna), together with its subsidiaries, is a health services company. The Company offers medical, dental, disability, life and accident insurance and related products and services. The Company’s segments include Global Health Care, Global Supplemental Benefits, Group Disability and Life, and Other Operations and Corporate.

Analyst Recommendations for CIGNA (NYSE:CI)

Receive News & Ratings for CIGNA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CIGNA and related companies with Analyst Ratings Network's FREE daily email newsletter.